Antipyretic TRIZ Cases

Conventional OA therapies may relieve symptoms without slowing progression; phytonutrients target synovitis and cartilage degradation.

Selective diamine derivatives inhibit LTA4 hydrolase, potentially lowering LTB4 production and downstream inflammation in chronic inflammatory diseases.

Citric, fumaric, and tartaric acid stabilizers protect Compound A formulations during storage while targeting KDM1A with reduced toxicity.

Controlled excipient ratios turn acetone-extracted gamboge resin into a tablet that releases drug over 12–72 hours while maintaining blood levels.

Hydrophobic chromatography separates clipped variants from intact activatable antibodies to improve composition purity, yield, and therapeutic safety.

Coupling allergen peptides with CTLA-4 or PD-1 on VLP surfaces aims to induce specific tolerance while limiting severe reactions from direct allergen dosing.

Isolate TRAMlo neutrophil and monocyte subsets to reduce inflammation and improve vascular integrity in atherosclerosis.

Methylcellulose and hyaluronan form a local depot that releases anesthetic for 48 hours to 5 days, reducing infusion and opioid reliance.

Chronic skin symptoms remain difficult to relieve; multi-extract herbal formulations combine plant-derived bioactives in creams, ointments, and juices.

An optimized glycyrrhizin dose in animal food targets atopic dermatitis, inhibiting IL-5 release without hypertension or kidney issues.

An oral Bifidobacterium longum RAPO composition targets inflammation and fibrosis through gut-lung axis immune modulation.

Current lupus treatments may miss BDCA2-linked immune dysfunction; this case uses targeted antibodies in a subcutaneous formulation.

Genetic polymorphisms guide CD30L inhibitor selection for Crohn’s disease and primary sclerosing cholangitis, targeting patients likely to benefit.

Racemic loxoprofen can limit pharmacological selectivity; separating chiral isomers identifies derivatives with stronger joint activity and lower dose needs.

Tumor-driven arginase lowers L-arginine and suppresses immunity; these compounds block the enzyme to restore immune responsiveness.

CO measurements are correlated with biomarkers to support accessible, non-invasive assessment of ASD, inflammation, and autoimmunity.

Stabilizers and surfactants protect anti-OX40 antibodies from denaturation, aggregation, and precipitation during handling, shipping, and storage.

Folic acid targets folate receptors while aminoclay stabilizes drug payloads, supporting selective delivery and reducing systemic exposure.

High-concentration anti-TNFα formulations use Fc substitutions and selected excipients to limit aggregation and support less frequent dosing.

Learn how Fc-containing multispecific antibodies block IL-4R and IL-31 while remaining stable above 100 mg/mL for subcutaneous injection.

Rabbit-derived IL-4R variable domains combine high-affinity binding and stability for multispecific antibodies blocking IL-4 and IL-13 signaling.

Pitcher plant herbal preparations adjust fibrinogen toward homeostatic levels while supporting fibroblast activity for inflammation and tissue repair.

Defined heavy- and light-chain CDRs target WARS1 selectively, limiting cross-reactivity with other aminoacyl-tRNA synthetases.

HPMC matrix and particle-size control help release acetone-extracted gamboge resin over 12–72 hours while maintaining drug levels.

Localized topical delivery combines cannabidiol, menthol, camphor, and herbal extracts to relieve pain and inflammation while avoiding systemic NSAID side effects.

Selective CDR grafting and framework residue retention help anti-C-MET antibodies preserve affinity while reducing immunogenicity.

Targeted antibodies bind SCF248 to block c-Kit interaction, reducing immune cell activation, chronic inflammation, and fibrosis.

Small-molecule Formula (I) compounds modulate TNF alpha activity while reducing cardiac toxicity linked to benzimidazole cores.

Extracted IL-6-binding domains with fatty acid substituents address antibody cost and immunogenicity while supporting oral dosing.

Separating the NSAID derivative from its solvent during storage preserves stability while enabling transdermal use and avoiding gastrointestinal reactions.